These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 23252778)

  • 1. Commentary: a gastrin antagonist against carcinoids--implications for PPI-induced hypergastrinaemia.
    McCarthy DM
    Aliment Pharmacol Ther; 2013 Jan; 37(2):276-7. PubMed ID: 23252778
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A.
    Fossmark R; Sørdal Ø; Jianu CS; Qvigstad G; Nordrum IS; Boyce M; Waldum HL
    Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1067-75. PubMed ID: 23072686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised trial of the effect of a gastrin/CCK
    Boyce M; van den Berg F; Mitchell T; Darwin K; Warrington S
    Eur J Clin Pharmacol; 2017 Feb; 73(2):129-139. PubMed ID: 27796466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.
    Moore AR; Boyce M; Steele IA; Campbell F; Varro A; Pritchard DM
    PLoS One; 2013; 8(10):e76462. PubMed ID: 24098507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist.
    Boyce M; Thomsen L
    Scand J Gastroenterol; 2015 May; 50(5):550-9. PubMed ID: 25665655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.
    Boyce M; Moore AR; Sagatun L; Parsons BN; Varro A; Campbell F; Fossmark R; Waldum HL; Pritchard DM
    Br J Clin Pharmacol; 2017 Mar; 83(3):466-475. PubMed ID: 27704617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reflections on some pilot trials of gastrin receptor blockade in pancreatic cancer.
    Black JW
    Eur J Cancer; 2009 Feb; 45(3):360-4. PubMed ID: 19131241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice.
    Aasarød KM; Ramezanzadehkoldeh M; Shabestari M; Mosti MP; Stunes AK; Reseland JE; Beisvag V; Eriksen EF; Sandvik AK; Erben RG; Schüler C; Boyce M; Skallerud BH; Syversen U; Fossmark R
    J Endocrinol; 2016 Aug; 230(2):251-62. PubMed ID: 27325243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential clinical indications for a CCK
    Boyce M; Lloyd KA; Pritchard DM
    Curr Opin Pharmacol; 2016 Dec; 31():68-75. PubMed ID: 27710813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follow-up of patients with ECL cell-derived tumours.
    Sagatun L; Fossmark R; Jianu CS; Qvigstad G; Nordrum IS; Mjønes P; Waldum HL
    Scand J Gastroenterol; 2016 Nov; 51(11):1398-405. PubMed ID: 27309188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum chromogranin A reflects regression of metastatic carcinoid during prolonged octreotide treatment.
    Pregun I; Gergics P; Dabasi G; Igaz P; Racz K; Tulassay Z
    Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):386-7. PubMed ID: 20611009
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of endogenous gastrin in the development of enterochromaffin-like cell carcinoid tumors in Mastomys natalensis: a study with the specific gastrin receptor antagonist AG-041R.
    Chiba T; Kinoshita Y; Sawada M; Kishi K; Baba A; Hoshino E
    Yale J Biol Med; 1998; 71(3-4):247-55. PubMed ID: 10461356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Commentary: netazepide for gastric acid suppression--another kid on the block?
    Metz DC
    Aliment Pharmacol Ther; 2012 Aug; 36(3):294-5. PubMed ID: 22747455
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of ECL cell carcinoids with octreotide LAR.
    Fykse V; Sandvik AK; Qvigstad G; Falkmer SE; Syversen U; Waldum HL
    Scand J Gastroenterol; 2004 Jul; 39(7):621-8. PubMed ID: 15370681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
    Jianu CS; Fossmark R; Syversen U; Hauso Ø; Fykse V; Waldum HL
    Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum chromogranin A reflects regression of metastatic carcinoid during prolonged octreotide treatment.
    Pregun I; Gergics P; Dabasi G; Igaz P; Racz K; Tulassay Z
    Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):476-7. PubMed ID: 19382304
    [No Abstract]   [Full Text] [Related]  

  • 17. Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis.
    Massironi S; Zilli A; Fanetti I; Ciafardini C; Conte D; Peracchi M
    Dig Liver Dis; 2015 Nov; 47(11):978-83. PubMed ID: 26321479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time-course of deactivation of rat stomach ECL cells following cholecystokinin B/gastrin receptor blockade.
    Ding XQ; Lindström E; Håkanson R
    Br J Pharmacol; 1997 Sep; 122(1):1-6. PubMed ID: 9298521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs.
    Campana D; Nori F; Pezzilli R; Piscitelli L; Santini D; Brocchi E; Corinaldesi R; Tomassetti P
    Endocr Relat Cancer; 2008 Mar; 15(1):337-42. PubMed ID: 18310299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response: Randomised trial of the effect of a gastrin/CCK2 receptor antagonist on esomeprazole-induced hypergastrinaemia: evidence against rebound hyperacidity.
    Boyce M; van den Berg F; Mitchell T; Darwin K; Warrington S
    Eur J Clin Pharmacol; 2017 Jul; 73(7):925. PubMed ID: 28365794
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.